Lisdexamfetamine: A Review in ADHD in Adults
Author:
- 5 April 2016
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 30 (4) , 343-354
Abstract
Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult®; Tyvense Adult™) has been approved for use in adults with attention-deficit hyperactivity disorder (ADHD) under the EU decentralization procedure, with the first approvals in the UK, Sweden and Denmark. This approval reflects the results of three short-term trials in adults with ADHD in which fixed- or flexible-dose lisdexamfetamine produced significantly greater improvements than placebo in ADHD symptoms, overall functioning, executive functioning (including in patients with significant pre-existing impairment) and quality of life. Of note, a post hoc analysis of one of these studies suggested that the response to lisdexamfetamine was generally similar in treatment-naïve patients and those who had already received—and not responded satisfactorily to—previous ADHD therapies, including methylphenidate (MPH). Two further studies demonstrated the longer-term effectiveness of flexible-dose lisdexamfetamine in reducing ADHD symptoms, albeit maintenance of efficacy required ongoing treatment with the drug. Lisdexamfetamine was generally well tolerated in clinical trials, with an adverse event profile typical of that reported for other long-acting stimulants. Head-to-head comparisons with other long-acting agents, notably MPH and atomoxetine, are lacking. Nonetheless, on the basis of the available data, lisdexamfetamine provides a useful alternative option for the treatment of adults with ADHD, including those who have not responded adequately to previous ADHD therapies, including MPH.Keywords
This publication has 53 references indexed in Scilit:
- Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group studyBMC Psychiatry, 2013
- Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesADHD Attention Deficit and Hyperactivity Disorders, 2013
- Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adultsNeuropsychiatric Disease and Treatment, 2013
- Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorderBMC Psychiatry, 2013
- Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical StrategiesJournal of Central Nervous System Disease, 2012
- Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration studyBMC Pharmacology and Toxicology, 2012
- Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative studyHealth and Quality of Life Outcomes, 2012
- Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment designBehavioral and Brain Functions, 2010
- Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorderBehavioral and Brain Functions, 2009
- Treatment of adults with attention-deficit/hyperactivity disorderNeuropsychiatric Disease and Treatment, 2008